Please assess the completion status of the following clinical trial:

Trial Title: Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria::~* Meets DSM-IV criteria for Major Depressive Disorder~* 18 to 75 years of age and able to provide legal consent~* Referred to Stanford ECT service by treating physician for unilateral electroconvulsive therapy with inpatient hospitalization~* Competed process for consenting to the clinical use of ECT according to California State law~* Females of childbearing potential will be required to use a double-barrier method of contraception, which includes foam and either condom and diaphragm, IUD, and/or implant during study.\&#xA; Exclusion Criteria:- Treatment with ECT in the 6 months prior to screening~* Meets criteria for drug or alcohol abuse or dependence in the 6 months prior to screening~* Use of alcohol or illegal drugs within seven days of randomization or during study. Patients may be excluded for use during a period greater than 7 days, per study physician's discretion~* Presence of unstable or untreated cardiovascular disease, hypertension, or endocrine disorder as determined by the investigator~* use of antipsychotic, antidepressant, or other prescription medications unless dose is stable for at least 7 days prior to randomization.~* Use of any investigational treatment within 30 days of randomization~* Previous allergic reaction to memantine or drugs of similar chemical structure.~* Women who are pregnant or breastfeeding are not advised to participate in the research study~* Any neurological disorder or organic brain condition that would confound neurocognitive testing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Oral Capsule (Type: PLACEBO_COMPARATOR): Patients received a placebo capsule starting the day before ECT begins and while receiving ECT
- memantine (Type: EXPERIMENTAL): Patients receive memantine starting the day before ECT begins and while receiving ECT

Based on this trial design, predict the completion outcome and termination type (if applicable).